Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR By Ogkologos - July 28, 2025 706 0 Facebook Twitter Google+ Pinterest WhatsApp Final results from the IMpassion031 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR October is National Dental Hygiene Month October 1, 2020 Combination immunotherapy for advanced bowel cancer approved for NHS in England June 16, 2021 Breast Cancer Patient Does Head-Shaving Photo Shoot in Hopes of Inspiring... March 24, 2021 Efficacy of Afamitresgene Autoleucel for HLA-A*02-positive and MAGE-A4-positive Synovial Sarcoma Following... April 2, 2024 Load more HOT NEWS Researchers Create Modified Antibodies to Target RAS and p53 in Cancer A Large Genomic Analysis Identifies That Persistent Tumour Mutational Burden Is... Extra or Missing Chromosomes May Help Cancer Cells Survive Treatment Curbing Production of Immune Checkpoint Protein Slows Liver Cancer in Mice
